Fidaxomicin versus Vancomycin for <i>Clostridium difficile</i> InfectionThomas Louie(Alberta Health Services), Youe‐Kong Shue(Efficient Pharma Management (Taiwan))New England Journal of MedicineFebruary 2, 201110.1056/nejmoa0910812Cited by 1,571SaveCiteExport RISWatch citationsRelated PapersEfficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection|Drugs|2022|273Hypoxia-Inducible Factor Signaling Provides Protection in Clostridium difficile-Induced Intestinal Injury|Gastroenterology|2010|102Publisher Correction: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection|Drugs|2022|6